Skandinaviska Enskilda Banken (SEB)
RETA

Skandinaviska Enskilda Banken (SEB)’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-94,646
Closed -$9.65M – 1004
2023
Q2 		$9.65M Buy
+94,646
New +$8.96M 0.06% 271

Other funds holding RETA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s RETA Position: Q3 2023 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 94,646 shares — an estimated $9.65M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in RETA in Q2 2023 and held it in 1 quarter. The position peaked at $9.65M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 94,646 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $9.65M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2023 and held it in 1 quarter.
  • Skandinaviska Enskilda Banken (SEB)'s Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $9.65M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2023, filed 9 Nov 2023.